1. Volume 61, Issue 4, Pages 810-817 (April 2012)
Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study 
Michael Rink, Felix K. Chun, Roland Dahlem, Armin Soave, Sarah Minner, Jens Hansen, Malgorzata Stoupiec, Cornelia Coith, Luis A. Kluth, Sascha A. Ahyai, Martin G. Friedrich, Shahrokh F. Shariat, Margit Fisch, Klaus Pantel, Sabine Riethdorf 
European Urology 
Volume 61, Issue 4, Pages (April 2012)
DOI: /j.eururo
Copyright © 2012 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan-Meier plots of (A) recurrence-free, (B) cancer-specific, and (C) overall survival stratified according to circulating tumor cells (CTC) status (positive vs negative) in 100 patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial carcinoma of the bladder.
SD=standard deviation.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier plots of (A) recurrence-free, (B) cancer-specific, and (C) overall survival stratified according to numbers of circulating tumor cells (CTC; 1 CTC vs ≥2 CTC/7.5ml) in 23 CTC-positive patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial carcinoma of the bladder.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

4. Fig. 3
Determination of human epidermal growth factor receptor 2 (HER2) status by (A) fluorescent in situ hybridization and (B) immunofluorescence using the CellSearch system. (A) Primary tumor with strong HER2 gene amplification (clusters of HER2 signals: red; CEP17 signals: green); (B) circulating tumor cells detected with the CellSearch system (0: HER2 negative; 1+: weak; 2+: moderate; 3+: strong intensity of HER2-specific immunofluorescence).
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions